HOLLISTON, Mass. , Nov. 21, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green , Chairman, President and CEO, and Michael Rossi , CFO will attend The Benchmark Company’s 8th Annual Discovery One-on-One Conference to be held on December 4, 2019 at the

Improves adjusted operating margins while taking actions to underpin next year’s profit and growth targets Q3 Revenue of $27.4 million Q3 Operating Loss (GAAP) of $(1.4) million ; Adjusted Operating Income (Non-GAAP) of $3.3 million Q3 GAAP EPS of $(0.07) ; Adjusted Diluted EPS (Non-GAAP) of $0.04

HOLLISTON, Mass. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that in connection with Yash Singh being named Executive Vice President, Cellular & Molecular Technologies on October 31, 2019 , the Compensation Committee of the Board of Directors approved

HOLLISTON, Mass. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Yash Singh has been named Executive Vice President, Cellular & Molecular Technologies, reporting to Chairman, President and CEO, Jim Green .  Singh will lead the newly formed Cellular

HOLLISTON, Mass. , Oct. 22, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its quarterly results for third quarter ended September 30, 2019 after market close on November 5, 2019 and hold a conference call to discuss the results for the third quarter on November 5,

HOLLISTON, Mass. , Oct. 21, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Ken Olson has been named Vice President and General Manager, Pre-Clinical Systems (DSI), reporting to Chairman, President and CEO, Jim Green .

HOLLISTON, Mass. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announces its strategic action plan and financial targets for rest of year 2019 through 2021. Key strategic actions and financial targets to position Harvard Bioscience for long-term profitable

HOLLISTON, Mass. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that its Board of Directors has elected Alan Edrick to Harvard Bioscience’s Board of Directors, effective September 3, 2019 . Bertrand Loy , Lead Independent Director, said “After

HOLLISTON, Mass. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) announced that Chairman, President and CEO, Jim Green , will be presenting at the Janney Montgomery Scott Healthcare Conference in New York City on September 9, 2019 at 9:05 a.m. EDT .

- GAAP and adjusted non-GAAP revenue of $29.6 million - GAAP and adjusted non-GAAP earnings per share of $(0.01) and $0.04 , respectively - 2019 guidance remains unchanged HOLLISTON, Mass. , July 25, 2019 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”), today announced